X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA GSK PHARMA NATCO PHARMA/
GSK PHARMA
 
P/E (TTM) x 18.8 68.2 27.6% View Chart
P/BV x 18.0 11.7 154.5% View Chart
Dividend Yield % 0.6 1.2 51.4%  

Financials

 NATCO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
GSK PHARMA
Mar-18
NATCO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8772,760 31.8%   
Low Rs4242,040 20.8%   
Sales per share (Unadj.) Rs223.4339.0 65.9%  
Earnings per share (Unadj.) Rs31.141.4 75.0%  
Cash flow per share (Unadj.) Rs40.345.9 87.7%  
Dividends per share (Unadj.) Rs5.0035.00 14.3%  
Dividend yield (eoy) %0.81.5 52.7%  
Book value per share (Unadj.) Rs219.5242.9 90.4%  
Shares outstanding (eoy) m33.0784.70 39.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.97.1 41.1%   
Avg P/E ratio x20.957.9 36.1%  
P/CF ratio (eoy) x16.152.3 30.9%  
Price / Book Value ratio x3.09.9 30.0%  
Dividend payout %16.184.5 19.0%   
Avg Mkt Cap Rs m21,504203,280 10.6%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1285,234 21.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,38928,715 25.7%  
Other income Rs m167545 30.6%   
Total revenues Rs m7,55629,260 25.8%   
Gross profit Rs m1,7935,059 35.5%  
Depreciation Rs m304380 80.1%   
Interest Rs m3662 18,310.0%   
Profit before tax Rs m1,2905,222 24.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m3091,892 16.3%   
Profit after tax Rs m1,0273,508 29.3%  
Gross profit margin %24.317.6 137.8%  
Effective tax rate %23.936.2 66.1%   
Net profit margin %13.912.2 113.8%  
BALANCE SHEET DATA
Current assets Rs m3,68121,815 16.9%   
Current liabilities Rs m3,12315,999 19.5%   
Net working cap to sales %7.620.3 37.3%  
Current ratio x1.21.4 86.5%  
Inventory Days Days8964 140.7%  
Debtors Days Days5919 314.1%  
Net fixed assets Rs m7,68512,475 61.6%   
Share capital Rs m331847 39.0%   
"Free" reserves Rs m6,67019,726 33.8%   
Net worth Rs m7,25920,573 35.3%   
Long term debt Rs m9556 15,915.0%   
Total assets Rs m11,95739,475 30.3%  
Interest coverage x4.52,612.0 0.2%   
Debt to equity ratio x0.10 45,107.2%  
Sales to assets ratio x0.60.7 85.0%   
Return on assets %11.78.9 131.1%  
Return on equity %14.217.1 83.0%  
Return on capital %20.726.2 79.0%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,445564 610.9%   
Fx outflow Rs m7037,429 9.5%   
Net fx Rs m2,743-6,865 -40.0%   
CASH FLOW
From Operations Rs m1,4404,728 30.5%  
From Investments Rs m-1,089-1,042 104.5%  
From Financial Activity Rs m-353-3,066 11.5%  
Net Cashflow Rs m-1620 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 50.7 2.9%  
Indian inst/Mut Fund % 7.8 10.2 76.9%  
FIIs % 16.6 23.8 69.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 15.4 168.8%  
Shareholders   25,395 102,036 24.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; Pharma Stocks Witness Buying(12:30 pm)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector and pharma sector witnessing maximum buying interest.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jul 17, 2018 03:01 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS